Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
May 3, 2007
By: Tim Wright
Editor-in-Chief, Contract Pharma
Bristol-Myers Squibb recently began construction at the site of its new biologics manufacturing facility in Devens, MA. The company has committed $750 million for the construction of the large-scale, multi-product bulk facility, which will be designed to accommodate potential future expansion. Phase I of the project will consist of four main buildings: a manufacturing structure that will house six 20,000-liter cell culture vessels and one purification train, a central utility building, an administrative/quality control building and a warehouse/storage structure. The facility is projected to be operational in 2009, and the company plans to submit the site for regulatory approval in 2010. Phase I of the facility will require a workforce of approximately 350 employees. Future expansion of the site could lead to a total of 550 or more employees. “The commitment to build this facility represents the single largest capital investment in the history of BMS, demonstrating the critical role we believe biologics will play in the future of our company,” said Jim Cornelius, chief executive officer, Bristol-Myers Squibb. “Building this facility provides additional manufacturing capacity to meet future patient need for our biologic therapies and helps position the company for long-term growth in this important area of medicine.” The facility will support increased production capacity for Orencia and manufacture commercial quantities of compounds currently in development, should they receive regulatory approval. The company’s investigational biologic compounds include treatments for certain types of cancers and solid organ transplant rejection. BMS currently manufactures biologic compounds in a company-owned facility in Syracuse, NY, and finishes and packages biologic compounds in Manati, PR. The Syracuse site will serve as the center of excellence in process development and early product launch for the company’s biologic compounds. The Manati facility will continue to finish and package biologic compounds. BMS also has biologic manufacturing agreements with third-party partners Lonza Biologics, Inc. and Celltrion, Inc.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !